![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.64 | 3.89% | 97.21 | 97.22 | 97.24 | 98.03 | 95.57 | 95.81 | 1,128,198 | 14:29:25 |
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded
Paris, July 25, 2024
Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73
Q2 pipeline progress
Other key updates
2024 business EPS guidance upgraded
Paul Hudson, Chief Executive Officer, commented:
“We are continuing our strong performance in 2024 and delivered broad-based, double-digit sales growth in the second quarter. We also made important progress in our pipeline of new medicines, including approvals for Dupixent in COPD, Kevzara in pediatric arthritis and ALTUVIIIO (EU) in hemophilia A. With the EU approval in COPD, Dupixent is the first-ever biologic medicine approved in this debilitating disease impacting hundreds of thousands of patients globally. As we accelerate our focused mid- and late-stage pipeline, we started a number of new phase 2 and phase 3 studies that will benefit patients in the future. We are well on track, delivering on our strategic priorities for Sanofi to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Underpinned by accelerated delivery of Sanofi’s transformation, we upgrade our earnings per share guidance for 2024.”
Q2 2024 | Change | Change at CER | H1 2024 | Change | Change at CER | |
IFRS net sales reported | € 10,745 m | +7.8% | +10.2% | € 21,209 m | +5.1% | +8.4% |
IFRS net income reported | € 1,113 m | -22.4% | — | € 2,246 m | -34.5% | — |
IFRS EPS reported | € 0.89 | -22.6% | — | € 1.80 | -34.3% | — |
Free cash flow(3) | € 854 m | -46.4% | — | € 545 m | -82.6% | — |
Business operating income | € 2,813 m | +3.2% | +8.3 % | € 5,656 m | -6.7% | +1.4% |
Business net income(1) | € 2,161 m | -0.7% | +4.0 % | € 4,380 m | -10.2% | -2.3% |
Business EPS(1) | € 1.73 | -0.6% | +4.0% | € 3.51 | -10.0% | -2.3% |
Changes in net sales are expressed at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9). The consolidated income statement for Q2 and H1 2024 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2023 business EPS was €8.11; (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 9). *Separation subject to market conditions and consultations of social partners and work councils.
Attachment
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions